Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Metastatic RCC After Bevacizumab Failure
NCT02056587Phase 4Completed
- Start
- Nov 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in metastatic renal cell carcinoma (mRCC). Primary endpoint: Proportion of progression-free patients at 2 months. Started Nov 2011; status: completed.
02
Drugs
everolimus
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02056587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02056587.